For a patient with NVAF and a CHA2DS2-VASc score of 3, which anticoagulant regimen is most appropriate?

For a patient with NVAF and a CHA2DS2-VASc score of 3, which anticoagulant regimen is most appropriate?

• A. Dabigatran 75 mg twice daily
• B. Rivaroxaban 20 mg once daily
• C. Apixaban 5 mg twice daily
• D. Edoxaban 60 mg once daily

Answer: (C)

The most appropriate anticoagulant regimen for a patient with non-valvular atrial fibrillation (NVAF) and a CHA2DS2-VASc score of 3 is Apixaban 5 mg twice daily. This choice is supported by several factors. Apixaban is a direct factor Xa inhibitor that is effective in reducing the risk of stroke and systemic embolism in patients with NVAF. The dosing of Apixaban is generally 5 mg twice daily, but it can be reduced to 2.5 mg twice daily if specific criteria are met, such as older age, lower body weight, or renal impairment. For a patient with a CHA2DS2-VASc score of 3, indicating a moderate risk of stroke, the standard 5 mg twice daily is appropriate and follows established guidelines. In terms of efficacy and safety, clinical trials have shown that Apixaban provides favorable outcomes with a lower risk of major bleeding complications compared to some of the other available anticoagulants. Therefore, the established dosing of Apixaban aligns with the need for effective anticoagulation in someone with a heightened risk of thromboembolic events. Dabigatran, rivaroxaban, and edoxaban also

The most appropriate anticoagulant regimen for a patient with non-valvular atrial fibrillation (NVAF) and a CHA2DS2-VASc score of 3 is Apixaban 5 mg twice daily. This choice is supported by several factors.

Apixaban is a direct factor Xa inhibitor that is effective in reducing the risk of stroke and systemic embolism in patients with NVAF. The dosing of Apixaban is generally 5 mg twice daily, but it can be reduced to 2.5 mg twice daily if specific criteria are met, such as older age, lower body weight, or renal impairment. For a patient with a CHA2DS2-VASc score of 3, indicating a moderate risk of stroke, the standard 5 mg twice daily is appropriate and follows established guidelines.

In terms of efficacy and safety, clinical trials have shown that Apixaban provides favorable outcomes with a lower risk of major bleeding complications compared to some of the other available anticoagulants. Therefore, the established dosing of Apixaban aligns with the need for effective anticoagulation in someone with a heightened risk of thromboembolic events.

Dabigatran, rivaroxaban, and edoxaban also